Crizotinib 150 MG Oral Pellet — RxCUI 2670166
RxNorm drug concept · Semantic clinical drug
RxCUI 2670166
Semantic clinical drug · SCD
● Current RxNorm concept 5 FDA products
5 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2670166
Official nameCrizotinib 150 MG Oral Pellet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped5
Package NDCs mapped5
Reported Medicaid activity (SDUD)130 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Crizotinib: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Crizotinib (Xalkori) targets cancers that carry specific gene changes — called ALK or ROS1 alterations — that drive tumor growth. It's approved for certain adults with metastatic n...
- What exactly does crizotinib treat, and how do I know if it's right for me?
- You can take Xalkori capsules with or without food — it's flexible. A high-fat meal does slightly reduce how much gets absorbed, but the effect is modest and the label allows eithe...
- Does it matter if I take Xalkori with food or on an empty stomach?
🕸️ Concept Web — How Crizotinib 150 MG Oral Pellet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Crizotinib 150 MG Oral Pellet
RxCUI 2670166 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Crizotinib
1148495IN
-
Crizotinib
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Xalkori
1148499BN
-
Xalkori
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Crizotinib Oral Pellet
2670165SCDF -
Crizotinib Oral Product
1165616SCDG -
Crizotinib Pellet Product
2670164SCDG -
Crizotinib Oral Pellet [Xalkori]
2670169SBDF -
Xalkori Oral Product
1186298SBDG -
Xalkori Pellet Product
2670168SBDG -
Oral Pellet
317691DF -
Oral Product
1151131DFG - +1 more in this family
-
Crizotinib Oral Pellet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Crizotinib 150 MG
2670163SCDC -
Crizotinib 150 MG Oral Pellet [Xalkori]
2670170SBD -
Crizotinib 150 MG [Xalkori]
2670167SBDC
-
Crizotinib 150 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Crizotinib 150 MG
SCDC · 2670163 -
Crizotinib Oral Pellet
SCDF · 2670165 -
Crizotinib Oral Product
SCDG · 1165616 -
Crizotinib Pellet Product
SCDG · 2670164
Brand-Name Concepts
-
Crizotinib 150 MG Oral Pellet [Xalkori]
SBD · 2670170 -
Crizotinib 150 MG [Xalkori]
SBDC · 2670167 -
Crizotinib Oral Pellet [Xalkori]
SBDF · 2670169 -
Xalkori Oral Product
SBDG · 1186298 -
Xalkori Pellet Product
SBDG · 2670168 -
Xalkori
BN · 1148499
📦 FDA Products & Package NDCs
5 products · 5 package NDCs
5 package NDCs map to RxCUI 2670166 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00069-0251-60 | 60 CAPSULE, COATED PELLETS in 1 BOTTLE (0069-0251-60) | Xalkori | Pfizer Laboratories Div Pfizer Inc | 2023-11-20 |
| 00069-0507-60 | 60 CAPSULE, COATED PELLETS in 1 BOTTLE (0069-0507-60) | Xalkori | Pfizer Laboratories Div Pfizer Inc | 2023-11-20 |
| 00069-1500-60 | 60 CAPSULE, COATED PELLETS in 1 BOTTLE (0069-1500-60) | Xalkori | Pfizer Laboratories Div Pfizer Inc | 2023-11-20 |
| 00069-8140-20 | 60 CAPSULE in 1 BOTTLE (0069-8140-20) | Xalkori | Pfizer Laboratories Div Pfizer Inc | 2011-08-26 |
| 00069-8141-20 | 60 CAPSULE in 1 BOTTLE (0069-8141-20) | Xalkori | Pfizer Laboratories Div Pfizer Inc | 2011-08-26 |
Observed labelers:
Pfizer Laboratories Div Pfizer Inc (5)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.